Eli Lilly and Company (ETR:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 818.68B |
| Revenue (ttm) | 50.64B |
| Net Income (ttm) | 15.69B |
| Shares Out | n/a |
| EPS (ttm) | 17.42 |
| PE Ratio | 52.17 |
| Forward PE | 33.62 |
| Dividend | 5.35 (0.58%) |
| Ex-Dividend Date | Nov 14, 2025 |
| Volume | 1,295 |
| Average Volume | 1,405 |
| Open | 914.10 |
| Previous Close | 927.40 |
| Day's Range | 911.60 - 914.10 |
| 52-Week Range | 535.80 - 971.10 |
| Beta | 0.37 |
| RSI | 54.58 |
| Earnings Date | Feb 6, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
This Healthcare Stock Could Be One of the Best Companies to Own in 2026
Eli Lilly should see more strong results thanks to its key growth driver, tirzepatide. The drugmaker can fend off the rising competition in the weight loss market.
The rise of obesity pills
2026 kicked off with the introduction of the Wegovy pill, the first ever non-injectable GLP-1 for obesity, from drugmaker Novo Nordisk. Competitors like Eli Lilly are racing to get their own versions ...
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.
Eli Lilly Stock Back In Focus After Long Slumber
Here's how we employ swing trading strategies of selling into strength, selling into weakness and cutting a loss quickly.
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company a...
Healthy Returns: What to expect from pharma at the JPM conference
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Schrödinger (SDGR) Partners with Eli Lilly for AI-Driven Drug Discovery
Schrödinger (SDGR) Partners with Eli Lilly for AI-Driven Drug Discovery
Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery
Schrödinger (SDGR) stock and Revvity (RVTY stock are in focus as firms join Eli Lilly (LLY) to integrate their software with LLY's TuneLab AI platform. Read more here.
Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.
Schrödinger (SDGR) Partners with Eli Lilly for AI Drug Discovery
Schrödinger (SDGR) Partners with Eli Lilly for AI Drug Discovery
Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight
On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatid...
Eli Lilly in pact with Schrödinger in AI-related drug discovery
Revvity, Lilly Partner To Expand Access To AI Drug Discovery Models
(RTTNews) - Revvity, Inc. (RVTY) on Friday announced a collaboration with Eli Lilly and Company (LLY) to make Lilly TuneLab, Lilly's AI-driven predictive modeling platform, available through the Revvi...
Eli Lilly (LLY) Partners with Schrodinger to Enhance Drug Discovery
Eli Lilly (LLY) Partners with Schrodinger to Enhance Drug Discovery
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software
Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.
Eli Lilly and JD.com have been highlighted as Zacks Bull and Bear of the Day
Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand accelerates worldwide.
Bull of the Day: Eli Lilly (LLY)
Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.
Eli Lilly: TOGETHER-PsA Study Meets Primary Endpoint At 36 Weeks
(RTTNews) - Eli Lilly and Company (LLY) announced positive topline results from the TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz and Zepbound compared to Taltz alone ...
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX
NEW YORK and NEW ORLEANS, Jan. 8, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Eli Lilly's (LLY) Taltz and Zepbound Show Positive Results in Psoriatic Arthritis Trial
Eli Lilly's (LLY) Taltz and Zepbound Show Positive Results in Psoriatic Arthritis Trial
Eli Lilly (LLY) Reports Positive Results with Psoriatic Arthritis Treatment
Eli Lilly (LLY) Reports Positive Results with Psoriatic Arthritis Treatment
Lilly's Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial
Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic arthritis treatment Taltz, improved arthritis symptoms and drove weight loss better than Tal...
Eli Lilly (LLY) Poised for Aggressive M&A Amid Biopharma Surge
Eli Lilly (LLY) Poised for Aggressive M&A Amid Biopharma Surge